Associated Papers
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A et al.
Cancer Science, 2025
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
39266536 (PubMed )
Supplement: 41467_2024_51713_MOESM5_ESM.xlsx › Data_2
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS et al.
Cancer Research Communications, 2022
36311816 (PubMed )
Supplement: crc-22-0314-s02.xlsx › Table_S6_List_of_mutations
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.
Thielmann CM et al.
Cancers, 2022
35565222 (PubMed )
Supplement: cancers-14-02090-s001.zip › cancers-1666969_Supplementary_material.pdf
Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes.
Lu J et al.
Cancer Medicine, 2021
33350171 (PubMed )
Supplement: CAM4-10-933-s001.xlsx › SNV
Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
Lin J et al.
Frontiers in Immunology, 2021
34211467 (PubMed )
Supplement: Table_1.xlsx › TableS2
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.
Barresi V et al.
Cancers, 2019
31480372 (PubMed )
Supplement: cancers-11-01279-s001.xlsx › S2_mutations
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS et al.
Cancer, 2016
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC et al.
The New England Journal of Medicine, 2010
Select a paper to view details